PubHealth.info® (An Information Portal on Public Health Issues / Topics, Presented in Collaboration with PakMed Biomedical Solutions)

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]


Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

Here you can find more than 42,000 article titles on "Contraception (Birth Control) and Family Planning" , along with their abstracts and bibliographic information (one of the world's largest collections of article titles on this topic), mentioned in various lists that are sorted/arranged according to the years of publication. You can view the bibliographic details and abstracts of these articles, by clicking the title of your required article. To view other lists of articles in the same category "Contraception (Birth Control) and Family Planning", please visit "Category Lists Homepage" or select a list from the following dropdown list of article titles.

 

List 58: Articles 28501-29000 (500 Articles)

To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles
  1. Influence of contraceptive hormones on hair growth (Letter) [Beeinflussung des Haarwachstums durch Kontrazeptive Hormone.]
  2. Influence of hormonal contraception on serum-lipoproteins. [Influence de la contraception hormonale sur les lipoproteines seriques.]
  3. Influence of hormonal contraceptives on the pituitary response to LH/FSH-releasing hormone.
  4. Influence of hormone contraceptives in the spectrum of free plasma acids. [Zum Einfluss hormonaler Kontrazeptiva auf das Spektrum der freien Plasmaamino-saevren.]
  5. Influence of oral contraception on fibrin stabilizing factor (factor XIII) [Beeinflussung des fibrinstabilisierenden Faktors (Faktor XIII) durch hormonelle Kontrazeption.]
  6. Influence of oral contraceptives on immediate postabortal pituitary-ovarian function.
  7. Influence of oral contraceptives on the development of cervical dysplasia and carcinoma in situ.
  8. Influence of parents, peers, and partners on the contraceptive use of college men and women.
  9. Influence of parents, peers, partners on the contraceptive use of college men and women.
  10. (Influences on the commitments by industry to contraceptive research and development) (Statement, March 9, 1978)
  11. Informed consent and legal considerations in family planning.
  12. Informed consent for family planning.
  13. Inhibition of hepatic demethylation of aminopyrine by oral contraceptive steroids in humans.
  14. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue - a new approach to birth control?
  15. Inhibition of testicular steroids by antibodies - a feasible approach to male contraception.
  16. Inner ear disturbance following long-term usage of hormonal contraceptives (author's transl) [Innenohrhorstorung nach Langzeiteinnahme hormonaler Kontrazeptiva.]
  17. Innovative projects in family planning and rural institutions in Bangladesh: report on a national workshop, Dacca, Feb. 1-4, 1978.
  18. Innovative social welfare/community development approaches to family planning: a micro study in Bangladesh.
  19. Instructions on combined oral contraceptives. (Letter)
  20. Insurance coverage of abortion, contraception and sterilization.
  21. Integrated approach to family planning, parasite control and nutrition.
  22. The Integrated Program for Family Planning Promotion and Parasite Control in Taiwan, Republic of China.
  23. Integrated Rural Development Programme: women's cooperative and family planning.
  24. Integrating nutritional and family planning education with food services in Korean day care centers--an evaluation.
  25. Integrating village family planning and primary health services - the Indonesian perspective.
  26. Integrating village family planning and primary health services: the Indonesian perspective.
  27. Intensive delivery system--Concerned Women for Family Planning.
  28. Interaction between family planning and health.
  29. Interactions between oral contraceptives and other drugs.
  30. Interactions of contraception and breast-feeding in developing countries. (Abstract only)
  31. The interactive effects of induced abortion, inter-pregnancy interval and contraceptive use on subsequent pregnancy outcome.
  32. Intercommunity variations in family planning program effort.
  33. Interference between oral contraceptives and other drugs. [Interferences entre contraceptifs oraux et medicaments.]
  34. Intermediate objectives for the monitoring of family planning services.
  35. International factfinding study: private sector marketing of contraceptives in eight developing countries. Vol. 1.
  36. International factfinding study: private sector marketing of contraceptives in eight developing countries. Vol. 2.
  37. International factfinding study: private sector marketing of contraceptives in eight developing countries. Vol. 3.
  38. International family planning programs, 1966-1975: a bibliography. (Abstract only)
  39. The International Planned Parenthood Federation's views on Depo-Provera. (Statement, August 8, 1978)
  40. International symposium: benefits and risks of birth control] [editorial. [Symposium international: bienfaits et risques du controle de la fertilite.]
  41. Intra epithelial carcinomas of uterine cervix with pills and without pills. [Cancers intra-epitheliaux du col uterin avec pilules et sans pilules contraceptives.]
  42. The intra-uterine contraceptive device - contraceptive or abortifacient?
  43. Intracranial venous thrombosis and oral contraceptives. [Flebotrombosis intracraneal y aniconceptivos orales: presentacion de dos casos y revision de la literatura.]
  44. Intrauterine contraception and its side-effects: effects of local proteinase inhibition.
  45. Intrauterine contraception complicated by inflammations. [Nitrodelozhi antikoncepce komplikovana zanety.]
  46. Intrauterine contraception in developing countries.
  47. Intrauterine contraception information for the patient.
  48. Intrauterine contraception with a copper-T variant. [Intrauterin kontraception med kobber-T-variant.]
  49. Intrauterine contraception worldwide.
  50. The intrauterine contraceptive device.
  51. Intrauterine contraceptive systems: their influence in intermenstrual bleeding.
  52. Intrauterine copper contraceptive devices and allergy to copper and nickel. (Letter)
  53. Intrauterine progesterone for contraception.
  54. Intravenous glucose tolerance after 18 months on progestogen or combination-type oral contraceptive.
  55. Introduction (to Birth Rates and Birth Control Practice)
  56. Introduction (to current concepts in contraception)
  57. Introduction (to oral contraceptives)
  58. The introduction of family planning program to Akhas in Thailand.
  59. Involvement of community in family planning service delivery: community based distribution (some experiences)
  60. Involving experts/professionals in family planning program: a Japanese case.
  61. IPAVS family planning thesaurus with a focus on contraceptive sterilization.
  62. Irreversible contraceptive methods. [Metodos anticonceptivos irreversibles.]
  63. Is there an alternative to the family planning programme in India?
  64. Is there hope? Fertility and family planning in a rural Egyptian community.
  65. Is there hope? fertility and family planning in a rural Egyptian community.
  66. Isotope nephrographic studies during hormonal contraception using Deposiston. [Isotopennephrographische Untersuchungen waehrend der hormonalen Kontrazeption mit Deposiston.]
  67. The IUD and PID: Is the contraceptive the culprit??
  68. The IUD as a contraceptive device: a self-instructional module for doctors, nurses and midwives.
  69. Journalism and the popularization of NFP (natural family planning) in Japan.
  70. A KAP study on MTP acceptors and their contraceptive practice.
  71. Kenya's maternal, child health/family planning (MCH/FP) program: A summary. (Statement, April 26, 1978)
  72. The Kimia Farma oral contraceptive production facility in Bandung, Indonesia, June 1978.
  73. Kinship structures and family planning behavior.
  74. Knowledge and attitudes of health personnel in matters of birth control. [Information et attitudes du personnel de sante en matiere de regulation des naissances.]
  75. Knowledge of contraception.
  76. Knowledge, attitude and practice of family planning in a rural Ceylonese community.
  77. Knowledge, attitude and practice of family planning of an ethnic Chinese community in Kotamadya Palembang South Sumatra.
  78. Knowledge, attitude, and practice on family planning among the Mountain State Agricultural College students.
  79. Kweichow planned parenthood conference.
  80. Labeling exclusive terminology discussed by OTC contraceptive panel.
  81. Lactation for delaying re-establishment of menstruation and its possible role in family planning.
  82. Laparoscopic sterilization at an outpatient clinic: physical and psychological reactions to the first 200 women who received sterilization operations at the Planned Parenthood Center of Syracuse, N.Y.
  83. Large majority of Americans favor legal abortion, sex education and contraceptive services for teens.
  84. Legal barriers to availability of contraceptives for adolescents. (Statement, March 1, 1978)
  85. Legal corner: birth control, abortion and the law: where we stand.
  86. LH-RH analogues have potential role in contraception for males.
  87. Liabilities regarding sterilization, abortion, contraceptive counseling remain unclear.
  88. Life table analysis of the effectiveness of contraceptive methods using an APL computer program.
  89. The limitations of family planning programmes in the developing nations.
  90. The link between nutrition and family planning.
  91. The literature activities of the Project Side-Effects of Oral Contraceptives - Pilot Phase.
  92. Literature and art propaganda: source materials on family planning (Editorial)
  93. Liver adenoma associated with oral contraceptive pill administration.
  94. The liver and oral contraceptives. [Foie et pilule contraceptive.]
  95. Liver cell adenoma associated with oral contraceptive hormone therapy.
  96. Liver function in Thai women using different types of hormonal contraceptive agents.
  97. Liver function studies under the effect of four sequential hormonal contraceptives. [Leberfunktionsunterschungen unter dem Einfluss von 4 Sequenzpraeparaten zur hormonalen Kontrazeption.]
  98. Liver lesions caused by oral contraceptives. 1. Contraceptive-induced hepatosis in 85 women: recommendations for diagnosis and prophylaxis. [Leberschaeden durch orale Kontrazeptiva: 1. Mitteilung: Kontrazeptivabedingte Hepatosen bei 85 Frauen, Empfehlungen zur Diagnostik und Prophylaxe.]
  99. Liver neoplasia and oral contraceptives.
  100. Liver tumors and oral contraceptives.
  101. Liver tumors and oral contraceptives: pathology and pathogenesis.
  102. Liver tumors as adverse effects of contraceptives. [Lebertumoren als Komplikation von Ovulationshemmer.]
  103. Liver tumors associated with the prescription of oral contraceptives. [Tumeurs du foie associees a la prise de contraceptifs oraux.]
  104. Liver tumors associated with the use of contraceptive pills.
  105. Liver tumours associated with oral contraceptives.
  106. Local drug application as third method of contraception: results of a trial study. [La methode chimique locale comme troisieme voie en contraception: resultats d'experimentation.]
  107. Local estimates of family planning needs: a case study of the suitability of national data for making local estimates.
  108. Long acting contraceptive implants: an analysis of menstrual bleeding patterns.
  109. The long term use of injectable Norigest as a contraceptive in.
  110. Long-term action: a semi-licit contraceptive lures MDs.
  111. Long-term contraception by a single silastic implant-D containing norethindrone acetate in women: a clinical evaluation.
  112. A longitudinal study of success versus failure in contraceptive planning.
  113. Lowering of H.D.I. cholesterol by oral contraceptives. (Letter)
  114. Main results of the 1977 Hungarian fertility, family planning and birth control study: TCS-77.
  115. Male adolescent contraceptive utilization.
  116. Male contraception; clinical assessment of chronic administration of testosterone enanthate.
  117. Male contraceptive development: re-examination of testosterone enanthate as an effective single entity agent.
  118. Male interest in birth control increases.
  119. Male teenagers found willing to accept greater responsibility for contraception.
  120. Males and family planning: an attitudinal survey of 1200 teen and adult males in Merced County.
  121. Malnutrition and family planning.
  122. Management evaluation of the Family Planning International Assistance Project: Philippines - 26.
  123. Management planning for implementation of family planning programs.
  124. Managing contraceptive pill patients.
  125. Managing family planning activities at the clinic level.
  126. Managing family planning communication activities.
  127. Many teenagers and their parents talk together about contraception and decisions on abortion.
  128. Marketing family planning.
  129. Maternal and child health in Tunisia 1882-1970: a bibliography emphasing family planning and nutrition.
  130. The McCormick family planning program in Chiang Mai, Thailand.
  131. Measures of family planning acceptance in West Java and Central Java: preliminary results of the Indonesian value of children survey.
  132. Measuring the impact of family planning on birth rates.
  133. Mechanical contraception: the influence of parity on IUD usefulness.
  134. Medical contraception in man. [Contraccezione medica nell'uomo.]
  135. Medical interactions in the treatment with hormonal contraceptives. [Arzneimittelinteraktionen unter der Behandlung mit hormonalen Kontrazeptiva.]
  136. Medical students and contraception-investigation. [Laureandi in medicina e contraccezione.]
  137. Meeting of agencies conducting or directly supporting research on the biomedical aspects of family planning. September 11-12, 1978.
  138. Megaloblastic anemia caused by folic acid deficiency following administration of oral contraceptives: description of 2 clinical cases. [Anemia megaloblastica da carenza di acido folico conseguente a somministrazione di contraccettivi orali: descrizione di due casi clinici.]
  139. Men and family planning.
  140. Mennonite Central Committee and population control and family planning project.
  141. Menstrual regulation as a back-up for effective contraceptive practice.
  142. Mental birth control.
  143. Mesenteric venous thrombosis and oral contraceptives. [Mesenterialvenenthrombose und orale Ovulationshemmer.]
  144. Metabolic changes caused by oral contraceptives.
  145. Metabolic effects of oral contraceptives in relation to coronary heart disease in young women.
  146. Metabolic repercussions of oral contraception (Author's Transl) [Les repercussions metaboliques de la contraception orale.]
  147. Metabolic sequelae of oral contraceptives.
  148. Metabolic side effects and contraindications of oral contraceptives. [Consequences metaboliques et contre-indications des contraceptifs oraux.]
  149. Metabolic studies under administration of oral contraceptives: a review. [Stoffwechseluntersuchungen unter Einnahme oraler Kontrazeptiva: Eine Uebersicht.]
  150. Metabolism of an oral tryptophan load by women and evidence against the induction of tryptophan pyrrolase by oral contraceptives.
  151. Metals and contraceptive methods.
  152. Methionine metabolism and vitamin B-6 status in women using oral contraceptives.
  153. Method change and abandonment of contraception.
  154. Methods for determining supply and demand of family planning services. [Metodos para estimar la demanda y oferta de servicios de planificacion familiar.]
  155. Methods of fertility control: contraception, sterilization, and abortion.
  156. Methods of measuring the impact of family planning programmes on fertility: problems and issues.
  157. Mexico's first mass media campaign for family planning.
  158. Mexico: contraceptive prevalence survey.
  159. Microhemological studies in healthy subjects; effect of cigarette smoking and oral contraceptives on erythrocyte flexibility. [Mikrorheologische Untersuchungen an Gesunden: Auswirk ungen von Zigarettenrauchen und oralen Kontrazeptiva auf die Erythrozytenverform barkeit.]
  160. Middle-class Americans frown on premarital sex but think teens should be offered contraception.
  161. Migraine attacks and increased platelet aggregability induced by oral contraceptives.
  162. Minors and medical contraceptive services in Connecticut.
  163. Missionaries of Charity: natural family planning.
  164. Mode of action of oral contraceptives.

     

  165. Model programs for involving men in family planning.
  166. Modern contraceptive substances, their use and complications. [Savremena kontraceptivna sredstva, njihova primena i komplikacije.]
  167. Modern hormonal contraception (author's transl) [Hormonell antikonception av i dag.]
  168. Monitoring of the oral contraceptive 17-alpha-ethinyloestradiol-17 beta in human plasma by isotopic-dilution mass spectrometry.
  169. The monthly injectable contraceptive: a two-year clinical trial.
  170. More myomas caused by oral contraceptives? [Mehr Myome durch orale Kontrazeptiva?]
  171. More myomas due to oral contraceptives? [Mehr Myome durch orale Kontrazeptiva?]
  172. More research on the pill and alternative methods (of contraception)
  173. More widely controlled distribution of oral contraceptives. (Letter)
  174. Morphofunctional changes in the ovary after hormonal contraception. [Alteraciones morfofuncionales del ovario despues de la contraception hormonal.]
  175. Mortality during the use of oral steroid contraceptives: new British studies. [Mortalitu pri peroralni steroidni kontraceptci: nove britske studie.]
  176. Mortality risk with contraception low for some.
  177. Mother to mother: pregnancy, childbirth and family planning.
  178. Motivation of sterilization patients: implications for family planning.
  179. Motivations relating to family planning in Sri Lanka.
  180. MR (menstrual regulation) - contraception or euphemism?
  181. Multidisciplinary training in family planning.
  182. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone oenanthate and medroxyprogesterone acetate: 2. bleeding patterns and side effects.
  183. Multipurpose survey among Indians, 1977: fertility and family planning.
  184. A multivariate analysis of continued use of contraception among Philippine family planning acceptors.
  185. My mother said...the way young people learned about sex and birth control.
  186. My views on family planning in Bangladesh.
  187. Myocardial infarction and oral contraceptives. [Infarctus du myocarde et contraceptifs oraux.]
  188. Myocardial infarction in younger women: review of United States data on possible contributory factors, including use of oral contraceptives drugs.
  189. Myocardial infarctions during oral contraceptive medication: a discrete disease entity unrelated to coronary atherosclerosis. (Abstract only))
  190. National coordination of the Family Planning Program and its Integration into Health Institutions. [La coordinacion nacional del Programa de Planificacion Familiar y su ubicacion en las instituciones de salud.]
  191. National course on communications for health and family planning activities. [Cours national de communication pour les activites de sante et de planification familiale.]
  192. National family planning program in Korea: problems and future directions.
  193. National family planning programs in developing nations: a theoretical and empirical examination of the adoption process.
  194. The National Inventory of Family Planning Services: 1975 survey results.
  195. National meeting of Social Research on Family Planning. [1-reunion nacional de investigacion social en planificacion familiar.]
  196. The National Survey of Family Growth and the Health Examination Survey as means for studying contraception.
  197. National survey of fertility, family planning and communication in Guatemala (ENPAG/78). Pt. 1. Fertility and family planning. [Encuesta Nacional de fecundidad planificacion familiar y communicacion de Guatemala (ENPAG/78). Primera Parte. Fecundidad y planificacion familiar.]
  198. National training course in communication for health and family planning programs, April 3 to 28, 1978 (Report)
  199. National training course in communications for the health and family planning programs, Port-au-prince, Haiti, April 3-28, 1973. [Cours national d'entrainement en communication pour les programmes de sante et de planifacation familiale, Port-au-Prince, Haiti, 3-28 Avril 1973.]
  200. Natural family planning in America.
  201. Natural family planning methodology and research: past, present, future.
  202. Natural family planning.
  203. Natural family planning.
  204. Natural family planning. (Letter)
  205. Natural family planning. (Letter)
  206. Natural family planning. (Letter)
  207. Natural family planning. New drug-free, device-free birth-control methods everybody's talking about.
  208. (Natural family planning.) (Statement, March 7, 1978))
  209. Natural family planning: 1. the peak symptom and estimated time of ovulation.
  210. Natural family planning: client instruction guidelines: a manual for teacher development.
  211. Natural family planning: different methods.
  212. Natural family planning: sympto-thermic method.
  213. Natural family planning: the ovulation method.
  214. Natural methods of family planning said to be highly effective.
  215. Nature of the ovulation and the state of the preimplantation fetuses in the experimental administration of hormonal and neurotropic agents (including oral contraceptives) [Kharakter ovuliatsii i sostoianye predimplantatsi onikh zarodishey pri vvedeni nyek torikh ghormonalnikh i nyeirotropnikh sredstv v experimentye.]
  216. (The need for development of new methods of contraception.) (Statement, May 2, 1978.)
  217. (The need for long-acting contraceptives.) (Statement, August 10, 1978)
  218. The need for new contraceptives. (Presented to Symposium on Contraceptive Technology of the National Research Council at the National Academy of Sciences, Washington, D.C., May 16, 1978)
  219. Need new contraceptive method in next decade to make a major impact on population growth.
  220. The need to adapt and modify contraceptive technology to preferences of the target consumers of each country's population programs. Statement, May 2, 1978.
  221. Neoplasia and dysplasia of the cervix uteri and contraception: a possible protective effect of the diaphragm.
  222. Neuro-ophthalmologic accidents caused by hormonal contraception. [Accidents neuro-ophtalmologiques de la contraception hormonale.]
  223. New dimensions in family planning development, statement made at the Silver Jubilee Celebrations of the Family Planning Association of Sri Lanka, Colombo, 26 March, 1978.
  224. New frontiers of contraception.
  225. New leads on contraception: summarized discussion.
  226. New strategies for the delivery of maternal/child health and family planning services...in Mexico. Semi-annual report to the Agency for International Development. September 30, 1977-June 20, 1978.
  227. NFP (natural family planning) services and methods in Australia: a survey evaluation.
  228. NFP services and methods in Australia: a survey evaluation. Part 4: Methods of natural family planning.
  229. Nirodh: a contraceptive of the future.
  230. Nonclinical family planning programs.
  231. Norethisterone enanthate as a tricyclical contraceptive: comparative study. [Enantato de noretisterona comom contraceptivo triciclico: estudio comparativo.]
  232. Norethisterone enanthate may provide injectable contraceptive.
  233. Norethisterone oenanthate as an injectable contraceptive: a study of patients discontinuing treatment.
  234. Norethisterone oenanthate as an injectable contraceptive: use of a modified dose schedule.
  235. Number of developing countries are said to be adopting family planning programs.
  236. Number of sex partners not increased by giving contraception to teens.
  237. Nurse specialists in family planning: the results of a 3-year study.
  238. Nutrition: a factor in family planning acceptance.
  239. Observations and recommendations concerning voluntary surgical contraception in Nepal.
  240. Observations on family planning acceptors in Papua New Guinea.
  241. The occupational hazards of formulating oral contraceptives: a survey of plant employees.
  242. Occurrence of ovulation in women receiving the injectable contraceptive norethisterone oenanthate.
  243. On the influence of hormonal contraception on the secretion of tears (author's transl) [Ueber den Einfluss hormonaler Kontrazeptiva auf die Traenensekretion.]
  244. One year of Community based contraceptive distribution in the District of Howrah, West Bengal (Family Welfare Project)
  245. An open assessment of a new low dose oestrogen combined oral contraceptive.
  246. Operational research for family planning programs with Columbia University's Center for Population and Family Health.
  247. Ophthalmologic complications during use of oral contraceptives. [Ophthalmologische Komplikationen unter oraler Kontrazeption.]
  248. Ophthalmological complications after oral contraceptives (author's transl) [Powiklania oczne po doustnym stosowaniu srodkow antykoncepcyjnych.]
  249. Opinion leaders in an information-rich environment: some suggestions for family planning research in Nigeria.
  250. Oral and intrauterine contraception: a 1978 risk assessment.
  251. Oral contraception after 40: what is said, what is known. [La contraception orale apres 40 ans: ce qu'on dit, ce qu'on sait.]
  252. Oral contraception and the detection of carriers in haemophilia B.
  253. Oral contraception in the adolescent.
  254. Oral contraception with natural human oestrogen: differences between natural and artificial oestrogens.
  255. Oral contraception: physiologic and pathologic effects.
  256. Oral contraception: uncertainties and prospects. [Contraception orale: incertitude et perspectives.]
  257. Oral contraceptive associated liver tumors: an update.
  258. Oral contraceptive estrogen and plasma lipid levels.
  259. Oral contraceptive induced hypertension simulating primary aldosteronism.
  260. Oral contraceptive labeling.
  261. Oral contraceptive mortality.
  262. Oral contraceptive potencies and side effects.
  263. Oral contraceptive steroids and dysplasia and carcinoma of the cervix uteri.
  264. Oral contraceptive steroids and thrombophlebitis.
  265. Oral contraceptive therapy and benign hepatic lesions in females.
  266. Oral contraceptive therapy and systemic lupus erythematosus.
  267. Oral contraceptive use alters the balance of platelet prostaglandin and thromboxane synthesis.
  268. Oral contraceptive use: association with frequency of hospitalization and chronic disease risk indicators.
  269. Oral contraceptives - another look. (Editorial)
  270. Oral contraceptives according to the normophasic principle.
  271. Oral contraceptives and birth defects.
  272. Oral contraceptives and breach of warranty under the Uniform Commercial Code.
  273. Oral contraceptives and breast disease in premenopausal northern Albertan women.
  274. Oral contraceptives and breast disease: an epidemiological study.
  275. Oral contraceptives and cancer. (Interview)
  276. Oral contraceptives and cervix uteri cancer (Editorial) [P-piller og cancer cervicis uteri.]
  277. Oral contraceptives and cholangiocarcinoma. (Letter)
  278. Oral contraceptives and chronic polyarthritis: fewer new cases associated with "pill" use (editorial) [Orale Kontrazeptiva und chronische Polyarthritis: Weniger Neuerkrankungen bei anwendung der "Pille."]
  279. Oral contraceptives and emotional state.
  280. Oral contraceptives and endometrial cancer.
  281. Oral contraceptives and focal nodular hyperplasia of the liver: two case reports with electron-microscopic studies.
  282. Oral contraceptives and health. (Letter)
  283. Oral contraceptives and health: some recent observations.
  284. Oral contraceptives and liver tumors.
  285. Oral contraceptives and liver tumors. (Letter)
  286. Oral contraceptives and liver tumours.
  287. Oral contraceptives and nonfatal myocardial infarction.
  288. Oral contraceptives and nonfatal stroke in healthy young women.
  289. Oral contraceptives and platelet aggregation.
  290. Oral contraceptives and stroke in young women: a clinopathologic correlation.
  291. Oral contraceptives and the cardiovascular risk.
  292. Oral contraceptives and their influence on porphyrin concentrations in erythrocytes and urine.
  293. Oral contraceptives and thromboembolic disease.
  294. Oral contraceptives and thromboembolism.
  295. Oral contraceptives and vitamins. [Orale Kontrazeptiva und Vitamine.]
  296. Oral contraceptives can damage the liver.
  297. Oral contraceptives during lactation: transfer of contraceptive steroids and estradiol to human milk. [Abstract]
  298. Oral contraceptives in dermatology.
  299. Oral contraceptives problems. [Problema de los anticonceptivos.]
  300. Oral contraceptives sold in U.S.A. by progestogen and estrogen content 1973-June 1978 (based on dollar volume)
  301. Oral contraceptives, blood clotting and thrombosis.
  302. Oral contraceptives, hyperlipoproteinemia and ischemic heart disease. [Oralnye contratseptivy, ghiperproteidemia i ichemitcheskaia boliez sierdtsa.]
  303. Oral contraceptives, hypertension and nephrosclerosis (author's transl) [Ovulationshemmer, Hypertonie und Nephrosklerose.]
  304. Oral contraceptives, hypertension and teenagers.
  305. Oral contraceptives, smoking and modular hyperplasia of the liver.
  306. Oral contraceptives, smoking, and other factors in relation to risk of venous thromboembolic disease.
  307. Oral contraceptives, smoking, migraine, and food allergy. (Letter)
  308. Oral contraceptives, venous thrombosis, and varicose veins.
  309. Oral contraceptives, venous thrombosis, and varicose veins: Royal College of General Practitioners' Oral Contraception Study.
  310. Oral contraceptives, Vol. 2. 1978.
  311. Oral contraceptives--acceptability and side effects with combination pills.
  312. Oral contraceptives. [De anticonceptiepil.]
  313. Oral contraceptives: 1978 report of the Special Advisory Committee on Reproductive Physiology to the Health Protection Branch. [Contraceptifs oraux: 1978 rapport du Comite Consultatif special sur la Physiologie de la Reproduction Destine a la Direction Generale de la Protection de la Sante.]
  314. Oral contraceptives: a self-instructional module for doctors, nurses and midwives.
  315. Oral contraceptives: possible mediation of side effects via an estrogen receptor in liver.
  316. Oral contraceptives: Pt. 2.
  317. Oral-contraceptive use and bacteriuria in a community-based study.
  318. Oral-contraceptive-induced benign liver tumors--the magnitude of the problem. (Letter)
  319. The organization of family planning services: points to be noted and their interactions. [Organizacion de los servicios de planificacion familiar: niveles de atencion y sus interacciones.]
  320. Organized family planning services in the United States, 1968-1976.
  321. Ottawa Family Planning Clinic: experience with 3862 registrants.
  322. Ovarian pregnancy associated with intrauterine contraceptive devices.
  323. Overview of social welfare and family planning programmes in the Solomon Islands.
  324. The ovulation method and PP (Planned Parenthood)
  325. The ovulation method natural family planning. 4th ed.
  326. P and G explores contraceptives.
  327. Panel discussion (on use of oral contraceptives)
  328. Panel discussion: contraception and cancer.
  329. Panel on family planning: extension cycle, Escola Superior de Guerra, 5 de junho de 1978. [Painel sobre planejamento familiar: ciclo de extensao.]
  330. Papal ban on use of artificial birth control reaffirmed.
  331. Paraguay Contraceptive Prevalence Survey: variance estimation.
  332. Paraguayan contraceptive prevalence survey: demographic measurement. (Revised)
  333. Parents' aspirations for children and family planning in Iran.
  334. Parliament and birth control in the 1920s.
  335. Participation of community members in Family Planning Programs. [Participacion de los miembros de la comunidad en los programas de planificacion familiar.]
  336. Patentex-Oval: a contraceptive agent for topical use. [Patentex-Oval: srodek antykoncepcyjny do stosowania miejscowego.]
  337. Pathologic aspects of tumors and tumor-like lesions in women taking oral contraceptive hormones.
  338. Patient attitudes about two forms of printed oral contraceptive information.
  339. Patterns of abortion and contraceptive practice in Hungary.
  340. Patterns of family building and contraceptive use of middle-class couples.
  341. Patterns of serum LH and FSH in response to 4-hour infusions of luteinizing hormone releasing hormone in normal women during menstrual cycle, on oral contraceptives, and in postmenopausal state.
  342. Peers as recruiters: family planning communications of West Malaysian acceptors.
  343. Pelvic abscess in association with intrauterine contraceptive device.
  344. Pelvic actinomycosis and the intrauterine contraceptive device: a cyto-histomorphologic study.
  345. The perceived role of a family planning motivator counselor in the city of Cagayan de Oro.
  346. Personality and the use of oral contraceptives in British University students.
  347. Personnel administration for family planning programme managers.
  348. Perspectives in male contraception. [Perspectives de la contraception chez l'homme.]
  349. The pharmacist and family planning: review and report of a study.
  350. Philippines: first KAP on family planning survey on the youth.

     

  351. Philosophy of testing of the intrauterine progesterone contraceptive system.
  352. Physical consequences of contraception: the metabolic mischief of the pill.
  353. Pigmented skin lesions in babies born to underweight former oral-contraceptive users. (Letter)
  354. A pill for birth control.
  355. Pituitary adenomas and oral contraceptives. (Letter)
  356. Pituitary response to LHRH stimulation in women on oral contraceptives.
  357. Planned parenthood and childcare.
  358. Planned parenthood and women's development: programme inventory and project summaries.
  359. (Planning and evaluation in family planning services.) (Statement, February 28, 1978)
  360. Planning for sex, marriage, contraception, and pregnancy.
  361. Plasma concentrations of ethinylestradiol and d-norgestrel during two immediate postabortal oral contraceptive cycles.
  362. Plasma prolactin concentrations in women treated with low dose combination type oral contraceptives and in women using a d-Norgestrel-releasing intrauterine device.
  363. Plasma prolactin levels and contraception: oral contraceptives and intrauterine devices.
  364. Plasminogen activator levels in plasma and urine during exercise and oral contraceptive use.
  365. Platelet-aggregation during individual phases of menstrual-cycle and under oral-contraceptive therapy. [Die Plaettchenaggregation waehrend einzelner Zyklusphasen und unter Antiovulantientherapie.]
  366. The politics of Latin American family-planning policy.
  367. Population and development assistance: status and trends of family planning programs in developing countries: Kenya case study. (Statement, April 26, 1978)
  368. Population and family planning programs (9th ed.)
  369. Population and the influence of family planning.
  370. Population dynamics, fertility and family planning in a rural community: a study in Manchok, Southern Zaria, Nigeria.
  371. Population welfare through family planning.
  372. Possible immediate hypersensitivity reaction of the nasal mucosa to oral contraceptives.
  373. Post-coital contraception using dl-norgestrel/ethinyl estradiol combination.
  374. Post-coital contraception.
  375. Postcoital contraception by endometrial aspiration.
  376. Postcoital contraception.
  377. Postcoital contraception. [Postkoitale Kontrazeption.]
  378. Potencies of oral contraceptives. Letter.
  379. The potential of integrating population education elements into agricultural/rural development activities of major extension agencies academicians in population and family planning: A Malaysian case.
  380. The potential of reversible sterilization in family planning programs.
  381. A practical guide to incorporating infertility services in the framework of an existing family planning contraceptive program.
  382. A practical guide to incorporating infertility services in the framework of an existing family planning contraceptive program.
  383. Practice and non-practice of family planning in Egypt.
  384. Precautions to note before prescribing an oral contraceptive. [Precautions a observer avant de prescrire un contraceptif oral.]
  385. Preclinical evaluation of intrauterine progesterone as a contraceptive agent. 1. Local contraceptive effects and their reversal.
  386. Preclinical evaluation of intrauterine progesterone as a contraceptive agent. 3. Embryology and toxicology.
  387. Preclinical evaluation of intrauterine progesterone as a contraceptive agent: 2. Possible mechanisms of action.
  388. Preclinical evaluation of intrauterine progesterone contraceptive system.
  389. Preclinical intrauterine contraception.
  390. Predictors of family planning approval and adoption.
  391. Pregnancy, oral hormonal contraception and lipid bile composition. [Schwangerschaft, orale hormonale Kontrazeption und Gallenlipidzusammensetsung.]
  392. Pregnancy, parturition and contraception in 15 paraplegic women who have borne children. [Grossesse, accouchement, moyens do contraception a propos de 15 paraplegiques ayant eu des enfants.]
  393. Pregnancy-specific beta glycoprotein and chorionic gonadotropin-like immunoreactivity during the latter half of the cycle in women using intrauterine contraception.
  394. Preliminary report on the use of the combined multiload contraceptive intrauterine device (ML Cu-250)
  395. Premarital contraceptive use: a test of two models.
  396. The present and future of immunologic approaches to contraception.
  397. Present investigations for the development of male hormonal contraception. [Investigacion actual para el desarrollo de la anticonception hormonal masculina.]
  398. Present state of male contraception and future possibilities.
  399. A pretest experience of CBD record keeping system at Concerned Women for Family Planning.
  400. Primary peritoneal pregnancy in association with intrauterine contraceptive devices: two case reports.
  401. Private medical practitioners expand family planning participation.
  402. Problem-oriented approach to family planning.
  403. Problems in survey methodology relating to contraceptive sterilization.
  404. Problems in the evaluation of contraception. [Probleme bei der Bewertung von Kontrazeptiva.]
  405. Problems of contraception: exacerbation of cervical mucus. [Petits problemes de la contraception: exacerbation de la glaire cervicale.]
  406. Problems of contraception: pain accompanying or following the insertion of an intrauterine device. [Petits problemes de la contraception: douleurs qui accompagnent ou suivent la pose d'un sterilet.]
  407. Problems of contraception: the wire has disappeared. [Petits problemes de la contraception: le fil a disparu.]
  408. Proceedings of the National Conference on the Delivery of Family Planning Services in Rural America, Atlanta, Georgia, October 5-7, 1977.
  409. Proceedings of the Seminar on the Draft Two-Year Plan (1978-80) on Population Control and Family Planning, Dacca, Bangladesh, May 27, 1978.
  410. The production and use of an attitudinal film in birth control education.
  411. Production of fibrinolytic enzymes by macrophages on intrauterine contraceptive devices.
  412. Progestational contraception. [La contraception progestative.]
  413. Progestational potency of oral contraceptives: a polemic.
  414. Progestin-only contraceptives.
  415. Progestins and oral contraception: the role of progestins alone before the uncertainties and perspectives of oral contraception (interview) [Progestatifs et contraception orale: la place des progestatifs seuls devant les incertitu des et les perspectives dela contraception orale.]
  416. Program implications of discontinuation: the Botswana family planning follow-up study.
  417. The program of permanent limitation of fertility in the general management of materno-infant health and of family planning of the Ministry of Health and Assistance of Mexico. [Programa de limitacion permanente de la Fecundidad en la direccion genral de salud materno infantil y planificacion familiar de la Secretaria de Salubridad y Asistencia de Mexico.]
  418. The program-based channels for the diffusion of family planning.
  419. Programs which involve men in family planning.
  420. Programs which involve men in family planning.
  421. Progress report on Family Health Project, the Integrated Family Planning Project with Parasite Control and Nutrition.
  422. Progress report on The Integrated Project of Family Planning, Parasite Control and Nutrition in Sawah-Lunto, West Sumatra and Serpong, West Java, Indonesia.
  423. Progress report on The Malaysian Project for the Integration of Parasite Control and Family Planning.
  424. Progress report: Family Planning-Parasite Control-Nutrition Integration Pilot Project, Philippines.
  425. Prolactin and thyrotropin after stimulation by thyrotropin releasing hormone: a study under long-term administration of oral contraceptives. [Die Stimulierbarkeit der Sekretion von Prolaktin und Thyroid ea-stimulierendem Hormon mit Thyreotropin-Releasing-Hormon bei Langzeiteinnahme von oralen Kontrazeptiva.]
  426. Prolonged duration of pregnancy after hormonal contraception. [Schwangerschaftsuebertragung nach Hormoneller Kontrazeption.]
  427. Prostaglandin success as male contraceptive in animals.
  428. Psychiatric aspects in rejection of family planning.
  429. The psychiatrist in a family planning center. [Le psychiatre en centre de planification familiale.]
  430. Psychological and psychiatric aspects of the contraceptive methods. [Aspectos sicologicos y siquiatricos de los metodos anticonceptivos.]
  431. Psychological and socio-cultural factors as related to attitudes towards family planning among women in Bangladesh.
  432. Psychological aspects of contraceptive sterilization: theoretical framework, methodological considerations, and needed research.
  433. Psychological aspects of infertility, contraception and sexual dysfunctions.
  434. Psychological factors influencing the choice of contraceptive method.
  435. Psychology and contraception.
  436. Psychosocial aspects of contraceptive sterilization in women.
  437. Psychosocial determinants of fertility and contraception in Venezuela.
  438. Psychosocial research in family planning.
  439. Public health aspects of contraceptive sterilization.
  440. Pure crystalline estradiol pellet implantation for contraception.
  441. Putting the "family" in family planning services.
  442. Quantitative enhancement of dinitrochlorobenzene responsivity in women receiving oral contraceptives. (Abstract only)
  443. Quarterly report of CMAI Community Health and Family Planning Project, Bangalru for the 1st quarter 1978.
  444. The rabbit as an in vivo animal model for the study of vaginal contraceptive potency.
  445. Racism and the availability of family planning services in the United States.
  446. A radioimmunoassay for norethindrone (NET): measurement of serum NET concentrations following ingestion of NET-containing oral contraceptive steroids.
  447. A rapid history of contraception.
  448. Rationality and responsibility in family planning in traditional African society.
  449. Recent changes in contraceptive practice among American couples: results from the 1976 National Survey of Family Growth.
  450. Recent developments in oral contraception.
  451. Recent findings of research on hormonal contraception 2. The effect of an oral contraceptive on serum lipoproteins and skinfold thickness in young women.
  452. Recent findings of research on hormonal contraception 3., Ovulation induced by bromocriptine in normoprolactinaemic post-pill anovulation.
  453. Recent findings of research on hormonal contraception, 1. Interception: the use of post-coital oestrogens.
  454. Recent trend in preference of contraceptive method: pills down, diaphragm on rise.
  455. Recent trends in family building and contraception.
  456. Reduced high-density lipoprotein in women aged 40-41 using oral contraceptives: Consultation Bureau Heart Project.
  457. Reduction by mefenamic acid of increased menstrual blood loss associated with intrauterine contraception.
  458. Reduction in incidence of rheumatoid arthritis associated with oral contraceptives. Royal College of General Practitioners' Oral Contraceptive Study.
  459. Reflections on the alternatives for a German long-term study on side-effects of oral contraceptives.
  460. The Regional Training Course of the Control of Intestinal Helminthic Infections with Special Emphasis on Soil-Transmitted Helminthiasis, Family Planning Practice and Their Integrated Programme.
  461. Regulating contraceptive drugs and devices workshop report (Letter from PIACT)
  462. Relation of family planning adoption with selected socio-economic characteristics at district level.
  463. (The relationship between family planning and health) (Statement, March 8, 1978))
  464. Relationships between action programs and socioeconomic variables: a study of family planning and fertility differentials in four Colombian cities.
  465. The relative advantages of private voluntary organizations in responding rapidly and effectively to family planning in less developed countries. (Statement, May 3, 1978)
  466. Release of contraceptive steroids from sustained release dosage forms and resulting plasma levels.
  467. Removal of intra-abdominal intrauterine contraceptive devices.
  468. A renewed focus on contraception.
  469. Reply to paper by Dr. Edgren on Progestational Potency of Oral Contraceptives: a Polemic.
  470. Report lauds overseas family planning programs, questions AID reorganization.
  471. (Report of experience with Indonesian women and women's groups in rural development and family planning.) (Statement, April 20, 1978.)
  472. Report of the National Survey of Contraceptive Use: Costa Rica - 1978. [Informe de la Encuesta Nacional de Uso de Anticonceptivos Costa Rica - 1978.]
  473. Report of the National Survey on the use of contraceptives, Costa Rica, 1978. [Informe de la ancuesta nacional de uso de anticonceptivos, Costa Rica, 1978.]
  474. Report on a pilot study of village volunteers in family planning at Po Thong District (1975-1977), Angthong Province, Thailand.
  475. A report on the First Asian Regional Workshop on Injectable Contraceptives, Chiang Mai, Thailand, May 15-19, 1978.
  476. Report on the integration of a family planning program into a community mental health center.
  477. A report on UNFPA/EWPI Technical Working Group Meeting on Integration in Family Planning with Rural Development.
  478. Reproduction and family planning. [Reproduction et sante familiale.]
  479. Reproduction patterns and family structure: contraceptive practice and the family in Mexico.
  480. Reproductive physiology and contraceptive research.
  481. Reproductive risk, family planning: third report. [Riesgo reproductivo, planificacion familiar: tercer documento.]
  482. Research in family planning.
  483. The research management process: a module for family planning programme administrators.
  484. Research needs in population and family planning: a view from the developing world.
  485. (Research on and evaluation of the delivery of family planning services in the United States.) (Statement, February 23, 1978))
  486. Research on birth control technology.
  487. Research on male contraception. (Editorial)
  488. Research on mother-child risk: risk in reproduction, family planning. [Investigacion de riesgo materno-infantil.]
  489. Resource support services report: reporting system for the Project, Community-based Distribution of Contraceptives and Selected Health Supplies, Nicaragua: January 23-February 3, 1978. [memorandum]
  490. Resource support services report: technical assistance in the implementation of recommendations from the year-end evaluation for the project, community-based distribution of contraceptives and selected health supplies, Nicaragua, January 23- February 4, 1978. [Memorandum]
  491. Resource support services report: year-end evaluation of the project, Community-Based Distribution of Contraceptives and Selected Health Supplies, Nicaragua, December 5-14, 1977. [Memoranduum]
  492. Response by Dr. Edgren (on progestational potency of oral contraceptives). (Letter)
  493. Response to the safety concerns about Depo-Provera for contraception identified in the notice of opportunity for hearing.
  494. Results of the contraceptive prevalence/MCH survey in the Department of Boaco, Nicaragua: final report.
  495. Resumption of fertility after discontinuation of contraception.
  496. A retrospective analysis of family planning Papanicolaou smear data: lessons for the future. 2. Planned Parenthood's national experience, 1975.
  497. Return of fertility and outcome of pregnancy after discontinuing the use of Depo-Provera and other contraceptives. (Statement, August 9, 1978)
  498. Reversibility of contraceptive methods. [Reversibilite des methodes contraceptives.]
  499. Reversible changes in the eye after long term use of oral contraceptive agents. [Reverzibilne promene na oku usled duze upotrebe oralnih kontraceptivnih sredstava.]
  500. Reversible contraceptive methods. [Metodos an iconceptivos reversibles.]

To view other lists of the current category of articles, please visit "Category Lists Homepage"


Web PubHealth.info

© Copyrights PubHealth.info®, an information portal on public health. All rights reserved.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.